InvestorsHub Logo
Followers 57
Posts 5700
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Thursday, 12/01/2022 12:09:08 PM

Thursday, December 01, 2022 12:09:08 PM

Post# of 462084
We should thank the organizers of CTAD.

Having Lecanemab presenting early in the Conference has set a low bar for 2-73.

Lecanemab efficacy is marginal. Its safety is questionable. The drug and infusion costs are high.

I cannot believe Dr. Mc Farlane came all the way from Australia to announce a dud!

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News